Gift to establish Paul Rubacha Department of Real Estate

The Cornell Board of Trustees voted May 26 to approve the Paul Rubacha Department of Real Estate, to be managed between the College of Architecture, Art and Planning and the Cornell SC Johnson College of Business.

Immune therapy targets cells that cause leukemia relapse

Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia, according to a preclinical study by investigators at Weill Cornell Medicine.

New cancer subtype may illuminate treatment strategy

Researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have identified a previously unrecognized form of hormone therapy-resistant prostate cancer, as well as a set of molecules that drive its growth.

Five student groups win Cornell Tech Startup Awards

Cornell Tech awarded four student startup companies with pre-seed funding worth up to $100,000 in its ninth annual Startup Awards competition. A fifth company won a new startup award focused on public-interest technology.

Weill Cornell Medicine Commencement returns to Carnegie Hall

President Martha E. Pollack joined Deans Augustine M.K. Choi and Barbara Hempstead in conferring degrees on students graduating from Weill Cornell Medical College and Weill Cornell Graduate School of Medical Sciences, in the first in-person ceremony since the beginning of the COVID-19 pandemic. 

Benefactor Charles R. Lee ’61, trustee emeritus, dies at 82

Charles R. Lee was one of the university’s most active and generous ambassadors, and a tireless advocate for deeper connections across Cornell’s campuses and alumni communities.

The 2030 Project to marshal faculty to solve climate crisis

Declaring this the “decisive decade” for climate action, Cornell launched The 2030 Project: A Climate Initiative, which will mobilize world-class faculty to develop and accelerate tangible solutions to the climate challenge.

T cell behavior determines immunotherapy success

New research from Weill Cornell Medicine investigators may help explain why immunotherapy doesn’t work for some cancer patients.

Cell division finding could lead to new cancer treatments

A protein called CDC7, long thought to play an essential role early in the cell division process, is in fact replaceable by another protein called CDK1, according to a study by investigators at Weill Cornell Medicine and the Dana Farber Cancer Institute.